Mesoblast LimitedASX: MSB

Mesoblast Wins Deloitte Tech Fast 50 Leadership Award

· Issued by Mesoblast Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The award highlights Mesoblast's successful transition to a commercial-stage biotechnology company following the U.S. launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy. The Chief Executive expressed pride in the recognition, emphasizing the company's commitment to sustainable growth and delivering long-term value for shareholders.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

MESOBLAST WINS DELOITTE TECH FAST 50 LEADERSHIP & ENTERPRISE GROWTH AWARD New York, USA: November 19 and Melbourne, Australia: November 20, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the...

Mesoblast Limited on 6ix

Earlier from Mesoblast

All Mesoblast news releases